CEL-SCI (CVM) News Today $0.56 0.00 (0.00%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period CEL-SCI Corporation Appoints New Chief Financial and Operations OfficerNovember 17 at 4:15 AM | americanbankingnews.comU.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025November 7, 2024 | finance.yahoo.com3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity ConferenceNovember 4, 2024 | investing.comCEL-SCI files to sell 1M shares of common stock for holdersOctober 25, 2024 | markets.businessinsider.comUpstream Bio Inc.October 14, 2024 | money.usnews.comCalcium-mediated effect plays key role in cell disposal, researchers discoverOctober 11, 2024 | msn.comCEL-SCI (NYSE:CVM) Trading Down 3.8% - Here's What HappenedCEL-SCI (NYSE:CVM) Stock Price Down 3.8% - Time to Sell?October 11, 2024 | marketbeat.comCEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck CancerOctober 1, 2024 | finance.yahoo.comCVM Oct 2024 2.000 callSeptember 21, 2024 | ca.finance.yahoo.comCEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 CongressSeptember 10, 2024 | finance.yahoo.comCVM Jan 2025 1.500 callAugust 30, 2024 | ca.finance.yahoo.comCVM Sep 2024 1.500 callAugust 29, 2024 | ca.finance.yahoo.comCVM Oct 2024 1.500 callAugust 29, 2024 | ca.finance.yahoo.comCVM Apr 2025 1.000 putAugust 29, 2024 | ca.finance.yahoo.comCVM: Start Your Engines – FDA Green Lights Confirmatory Registration StudyAugust 28, 2024 | finance.yahoo.comCVM Oct 2024 0.500 call (CVM241018C00000500)August 28, 2024 | finance.yahoo.comCVM Oct 2024 1.500 put (CVM241018P00001500)August 28, 2024 | finance.yahoo.comCVM Sep 2024 1.000 callAugust 23, 2024 | ca.finance.yahoo.comPrincipal Investment Grd Corp Actv ETF (IG)August 23, 2024 | uk.finance.yahoo.comBiomotion Sciences.August 21, 2024 | money.usnews.comNew tool simplifies cell tracking data analysisAugust 17, 2024 | msn.comCEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial ResultsAugust 15, 2024 | stockhouse.com3 Penny Stocks to Watch Now, 7/30/24July 30, 2024 | msn.comCEL-SCI Announces Closing of $10.8 Million OfferingJuly 29, 2024 | finance.yahoo.com(SANSTAR.BO)July 27, 2024 | finance.yahoo.comStock Traders Purchase High Volume of Call Options on CEL-SCI (NYSE:CVM)CEL-SCI Co. (NYSE:CVM - Get Free Report) was the target of unusually large options trading activity on Friday. Traders acquired 2,966 call options on the stock. This is an increase of approximately 986% compared to the typical daily volume of 273 call options.July 26, 2024 | marketbeat.comCEL-SCI Announces Pricing of $10.8 Million OfferingJuly 26, 2024 | finance.yahoo.comNewly identified immune cell switch could control inflammationJuly 25, 2024 | msn.comNew model explains precise timing of viral cell burstingJuly 21, 2024 | msn.comCVI Holdings LLC Invests $1.68 Million in CEL-SCI Co. (NYSE:CVM)CVI Holdings LLC purchased a new position in shares of CEL-SCI Co. (NYSE:CVM - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 878,767 shares of the company's stock, valued at approximaJuly 14, 2024 | marketbeat.comCEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target PopulationJune 18, 2024 | businesswire.comDr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical AdvisorJune 6, 2024 | businesswire.comCel-Sci Corp.May 22, 2024 | money.usnews.comCVM: Confirmatory Study ClarityMay 21, 2024 | finance.yahoo.comCEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial ResultsMay 16, 2024 | businesswire.comInsider Buying: CEL-SCI Co. (NYSE:CVM) Director Acquires 20,000 Shares of StockMay 11, 2024 | insidertrades.comCEL-SCI Co. (NYSE:CVM) SVP Acquires $11,120.00 in StockMay 10, 2024 | insidertrades.comCEL-SCI Co. (NYSE:CVM) Director Acquires $27,800.00 in StockCEL-SCI Co. (NYSE:CVM - Get Free Report) Director Robert Eugene Watson bought 20,000 shares of the firm's stock in a transaction on Wednesday, May 8th. The stock was acquired at an average cost of $1.39 per share, with a total value of $27,800.00. Following the completion of the purchase, the director now owns 24,431 shares of the company's stock, valued at approximately $33,959.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.May 10, 2024 | marketbeat.comCEL-SCI Co. (NYSE:CVM) SVP Patricia B. Prichep Purchases 8,000 SharesCEL-SCI Co. (NYSE:CVM - Get Free Report) SVP Patricia B. Prichep purchased 8,000 shares of the stock in a transaction on Wednesday, May 8th. The shares were purchased at an average price of $1.39 per share, with a total value of $11,120.00. Following the acquisition, the senior vice president now directly owns 232,326 shares in the company, valued at $322,933.14. The purchase was disclosed in a legal filing with the SEC, which is available at this link.May 9, 2024 | marketbeat.comCEL-SCI gains as FDA greenlights confirmatory study for MultikineMay 8, 2024 | msn.comCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerMay 8, 2024 | businesswire.comCEL-SCI Appoints Mario Gobbo to Its Board of DirectorsApril 23, 2024 | businesswire.comCEL-SCI Co. (NYSE:CVM) to Post FY2024 Earnings of ($0.51) Per Share, Zacks Small Cap ForecastsCEL-SCI Co. (NYSE:CVM - Free Report) - Investment analysts at Zacks Small Cap reduced their FY2024 EPS estimates for shares of CEL-SCI in a note issued to investors on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings of ($0.51) per shareApril 17, 2024 | marketbeat.comChannel V Media Expands Content Marketing Division; Names Gabriella Bock Director of ContentApril 16, 2024 | businesswire.comResearch Analysts Offer Predictions for CEL-SCI Co.'s Q2 2024 Earnings (NYSE:CVM)CEL-SCI Co. (NYSE:CVM - Free Report) - Analysts at Zacks Small Cap issued their Q2 2024 earnings per share estimates for CEL-SCI in a report released on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten expects that the company will earn ($0.14) per share for the quarter. The consensusApril 16, 2024 | marketbeat.comCVM: Parallel Engagement on Four FrontsApril 15, 2024 | finance.yahoo.comScientists produce in vitro model of cell differentiation during early facial developmentApril 12, 2024 | msn.comResearchers discover two vesicle fusion mechanisms while studying vesicle movement in living cellsApril 9, 2024 | msn.comCVM CEL-SCI CorporationApril 6, 2024 | seekingalpha.comCross-species insights: Study finds calcium link in plant and animal immunityMarch 28, 2024 | msn.com Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address There is a little known company that is changing warfare (Ad)With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military. Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t CVM Media Mentions By Week CVM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CVM News Sentiment▼0.000.56▲Average Medical News Sentiment CVM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CVM Articles This Week▼11▲CVM Articles Average Week Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DiaMedica Therapeutics News Today Sagimet Biosciences News Today Incannex Healthcare News Today Skye Bioscience News Today Organigram News Today Actuate Therapeutics News Today LifeVantage News Today Scilex News Today Adverum Biotechnologies News Today Cardiol Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CVM) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
